The University of Barcelona closes a record-breaking year with six new spin-offs and €28 million in funding raised
The year 2025 marked a turning point for the University of Barcelona’s (UB) spin-off ecosystem. For the first time in its history, the UB promoted the creation of six science-based spin-offs in a single year, successfully completed a strategic sale, and the companies emerging from the university raised close to €28 million in private and competitive funding.
These figures reinforce the University of Barcelona’s position as a key player in knowledge transfer to industry and society, and demonstrate the maturity of its innovation model, focused on transforming research excellence into solutions with social and economic returns.
“The results achieved in 2025 highlight the strength of the University of Barcelona’s innovation ecosystem and the ability of its research to generate competitive companies with real impact. These milestones are the result of sustained work by the research community and of specialised support throughout all stages of spin-off creation and growth,” says Jose Conde, Head of the Business Creation Area at the Bosch i Gimpera Foundation, the University of Barcelona’s knowledge transfer office.
The spin-offs created in 2025 are:
- PulSensing (Faculty of Physics): high-performance microelectronics applied to medical imaging systems that enable the early diagnosis of cancer.
- Flavii Therapeutics (Faculty of Pharmacy and Food Sciences): epigenetic therapies targeting Alzheimer’s disease and other central nervous system disorders.
- OrganAID Holdings (Faculty of Medicine and Health Sciences, with UPF): a drug testing platform using patient-derived organoids and AI.
- Fedder AI (Faculty of Mathematics and Computer Science): an AI-based platform for fast and secure access to medical data to improve decision-making in healthcare.
- FetaLife Technologies (Faculty of Medicine and Health Sciences): a liquid incubator for extremely premature infants.
- Synpix (Faculty of Physics): infrared imaging technology to enhance the safety of autonomous vehicles.
This assessment also includes the sale of the University of Barcelona’s stake in the spin-off BeCytes Biotechnologies, an operation that exemplifies the complete value-creation journey of knowledge generated at the university.
Overall, these results consolidate the University of Barcelona’s leadership in the creation of innovative science-based companies and its contribution to the Sustainable Development Goals (SDGs), with a direct impact on areas such as health (SDG 3), innovation and industry (SDG 9), reduced inequalities (SDG 10) and sustainable cities and communities (SDG 11).